Dstock, I certainly don't know, but I believe the cost of making cancer fighting products has little to do with the price that will be charged for it. If a mass produced vaccine is just slightly less effective than DCVax-L it's price will very probably be just slightly less than DCVax-L.
It's been a long time since I took college chemistry, back then many people used tooth powder, rather than paste. When we analyzed what went into the powder, it became very clear that the cost of making the container was far greater than the cost of the powder inside. The point is, once you've paid back the research costs and costs of the equipment making the product, the cost of the product itself is often pennies.
DCVax-L is a very different animal. Whereas the cost of manufacturing a mass produced vaccine may well go into the hundreds of millions in equipment, what's in the vial is cheap. Assuming the approval of the EDEN unit, others have said that when mass produced each unit should cost tens of thousands, essentially less than will be charged for the first batch, making the EDEN a profitable unit on selling the first batch produced in it. Sure, it take a lot of other equipment, but it's already available in many places that could make DCVax-L if they had the EDEN unit.
All I'm suggesting is that DCVax-L can be more effective than mass produced products and sell at prices that are competitive.
I see our close is down $.07, so as of now we're only $.025 higher on filing with the UK, a sad commentary on how much control the MM's have on our price.
Gary
